Mitomycin Medac

Mitomycin, the active ingredient in Mitomycin Medac, is an antineoplastic antibiotic presented as a solution for intravesical use. It treats non‑muscle invasive bladder cancer in patients where bladder‑preserving therapy is indicated.

GNH USA supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin Medac is used as intravesical chemotherapy for urothelial malignancies. - Non‑muscle invasive bladder cancer (Ta/T1): reduces tumour recurrence after transurethral resection. - Carcinoma in situ of the bladder (CIS): eradicates flat malignant lesions and prevents progression. - Upper urinary tract urothelial carcinoma after endoscopic resection: provides local control when instilled retrograde.

Mitomycin may cause a range of adverse reactions following intravesical administration.

Common Side Effects: - Bladder irritation: burning or discomfort during urination. - Dysuria: painful urination. - Increased urinary frequency. - Hematuria: blood in urine. - Mild cystitis: inflammation of the bladder lining. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Systemic bone‑marrow suppression leading to anemia, neutropenia or thrombocytopenia. - Severe infection secondary to immunosuppression. - Renal toxicity or acute kidney injury. - Allergic reactions including rash, bronchospasm or anaphylaxis. - Pulmonary fibrosis or interstitial lung disease. - Life‑threatening hemorrhage.

Mitomycin should be used with careful clinical oversight to minimise risks. - Renal function assessment: ensure adequate creatinine clearance before instillation. - Bladder integrity: avoid use in patients with active urinary tract infection or gross hematuria. - Concomitant myelosuppressive therapy: monitor blood counts closely. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Storage: Store below 25°C: keep in original container, protect from light and moisture.

Mitomycin can interact with other agents that affect bone‑marrow function or renal clearance.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy (e.g., cyclophosphamide, doxorubicin): may cause profound cytopenias. - Nephrotoxic drugs (e.g., cisplatin, aminoglycosides): increase risk of renal injury. - Pelvic radiotherapy administered within 2 weeks: heightened bladder toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, direct oral anticoagulants): may exacerbate hematuria. - High‑dose NSAIDs: can impair renal excretion of mitomycin. - Immunosuppressants (e.g., azathioprine): may augment infection risk.